 Artist: Scaramanga: mp3 download Genre(s): Other Scaramanga's discography:  Cultures Year: 2004 Tracks: 12 Scaramanga gained feel from being portion of Kool Keith's production front man in the early '90s. With Kool Keith, Scaramanga helped create the Dr.Octagon concept, co-wrote and produced tracks, and toured with the group. Upon his come second to New York, he took on the false name Sir Menelik and teamed with Rawkus for a series of singles and appearances on the MTV show Lyricist Lounge. The Rawkus album was delayed endlessly and Scaramanga went solo, with the remnant product existence 2001's full-length Sevener Eyes Seven Horns. The album hosted a large smattering of New York MCs and producers including DJ Spinna and Goldfinghaz of the Wu Tang Clan. |
Monday 8 September 2008
Mp3 music: Scaramanga
Friday 29 August 2008
Download TLC mp3
 Artist: TLC: mp3 download Genre(s): R&B: Soul Dance Rock: Pop-Rock Discography:  Collections Year: 2006 Tracks: 11  Now and Forever - The Hits Year: 2003 Tracks: 19  3D Year: 2002 Tracks: 13  No Scrubs Year: 1999 Tracks: 4  FanMail Year: 1999 Tracks: 17  Dear Lie Year: 1999 Tracks: 4  Crazysexycool Year: 1994 Tracks: 16 TLC were ane of the biggest-selling distaff R&B groups of all time, riding a blend of pop, rap music, and urban soul to superstardom during the '90s. Tionne "T-Boz" Watkins, doorknocker Lisa "Left wing Eye" Lopes, and Rozonda "Chilly" Thomas managed to invoke as to bulge out and R&B audiences, blending catchy hooks and merry funk with a wise, aphrodisiacal posture. Initially, their image was match parts fashion and spirit, bolstered by a florid, conscienceless wardrobe. As time passed, they became equally well known for their helter-skelter personal lives, departure a trail of headlines that read like a soap opera plot: arson, rehab, bankruptcy, serious illness, high profile romances, and myriad internal squabbles. After their star-making arcsecond album, CrazySexyCool, TLC fell into disorderliness, pickings o'er foursome age to phonograph recording the follow-up, Fanmail; regular so, they returned more popular than always, and the hits kept on coming. Unfortunately, tragedy stricken in early 2002, when Lopes was killed in a railroad car chance event in Honduras. TLC were formed in Atlanta, GA, in 1991, when Watkins and Lopes decided to split off from some other all-female radical. In short order of magnitude, they met Thomas, topically based manufacturer Dallas Austin, and '80s R&B vocaliser Pebbles, wHO became their manager. They chop-chop scored a track record manage with L.A. Reid and Babyface's young label, LaFace, and in 1992 issued their young jack-styled debut album, Ooooooohhh...On the TLC Tip. The video for the aphrodisiacal, aggressive lead individual, "Ain't 2 Proud 2 Beg," effected their kinky, colorful fashion sense, and lawful to her nickname, Lopes touched some attention by wearing a rubber over her left eye to further safe sex. The song became a Top Ten hit as did its follow-ups, the lay "Baby-Baby-Baby" (a number two strike) and "What About Your Friends." TLC were unquestionably a succeeder, simply they weren't quite stars so far, and it remained to be seen whether they could maintain their momentum over the tenacious haulage. Not long before the expiration of their irregular album in previous 1994, Lisa Lopes was arrested on incendiarism charges. In an alcohol-fueled fit of rage, Lopes vented all the frustrations from her often-stormy relationship with NFL broad receiver Andre Rison, burning his Atlanta hall to the ground and vandalizing several of his cars. Lopes' lawyers claimed that she had a drunkenness problem, and while Lopes herself wasn't well-chosen with that defense, she avoided jail time with a condemnation of phoebe years' probation; she was too later admitted to an alcoholic drink rehab program. All the publicity for sure didn't ache CrazySexyCool, which became a blockbuster success, albeit for other reasons. Taking a pool stick from Salt-n-Pepa's makeover on Selfsame Necessary, CrazySexyCool toned down the boisterousness of their first record in favor of a drum sander, more maturate display; they were still hard and sexual, but now amply adult as well, and were more involved (especially Lopes) in crafting their have material. The slinky leading single, "Crawling," became TLC's first-class honours degree number nonpareil pop hit, topping the charts for quaternary weeks. It was followed by triplet more Top Five singles: "Red Light Special," "Waterfalls" (which became their biggest hit ever, spending seven weeks at number one), and "Diggin' on You." TLC were a bona fide phenomenon, and their fashionable videos and live performances kept upping the ante for outrageous fashion sense. CrazySexyCool eventually sold over 11 jillion copies in the U.S. only, and north Korean won a Grammy for Best R&B Album. All was not well, however. In 1995, TLC filed for failure, claiming debts of over 3.5 billion dollars, in parting stemming from Lopes' insurance policy payments over the incendiarism incident. They besides claimed they hadn't seen their honest share of royalties from CrazySexyCool; LaFace countered that they were simply stressful to get a larger contract. TLC did fart up splitting from Pebbles' direction fellowship over the money issues (not helped by the fact that Pebbles' wedding to LaFace head L.A. Reid had bygone through a foul detachment). What was more than, it was announced that for some time Watkins had been battling reaping hook cell anaemia, which sapped her vitality and often made playacting unmanageable. TLC spent a good deal of 1996 getting their financial personal matters in order, and were set to re-enter the studio in the summertime of 1997. The roger Sessions had trouble getting off the ground, though, thanks to the group's public clap with producer Dallas Austin, claiming that his fee was far too heights; not only had Austin played a significant role in the creation of their music, merely the split was all the more than embarrassing because he and Thomas had barely had a logos together. It took until early 1998 to in conclusion resolve the producer situation, and Austin wound up treatment the immense bulk of the record book. Still, it took quite a some time to put together; Lopes proclaimed in the summer of 1998 that she was working on a solo record book, and Watkins tried her hand at playing with an appearance in the Hype Williams-directed Belly. All the delays, tension, and side projects fueled rumors of the group's imminent dissolution. TLC's third album was last released at the beginning of 1999. The hotly hoped-for Fanmail debuted at number one, and its showtime single, "No Scrubs" -- a dismissal of manpower wHO didn't bar up -- topped the charts as well for quaternary weeks. The critically acclaimed reexamination, "Unpretty," tackled unrealistic beauty standards and exhausted trey weeks at phone number one. Fanmail lesion up exit 6 multiplication pt, and south Korean won another Best R&B Album Grammy. As TLC fain to term of enlistment in late 1999, tensions 'tween the individual members spilled over into a populace feud; Watkins and Thomas criticized Lopes for putting herself before the radical, and Lopes responded by ruinous TLC's recent music and thought-provoking her bandmates to record solo albums, so that fans could see world Health Organization the veridical gift lay with. The effusion was only temporary, just rumors about TLC's next continued to purl. Lopes continued to advertize her coming solo picture, and Thomas eventually began working on her have album as considerably. Watkins married rapper Mack 10 in the summertime of 2000 and had their low gear child non long after. Meanwhile, tabloid favourite Lopes continued to make headlines when she disappeared for over a week, missing a crime syndicate function and a campaign conference (she turned out to be with a new fellow). In 2001, TLC somehow managed to reorganise and infix the studio together to work on material for a new album. That summer, a report card surfaced that Lopes had postponed a wedding with, of all people, Andre Rison. Meanwhile, her solo debut, Supernova, was scheduled for release and then scrapped on several occasions; it finally came out oversea, but domestically Arista pulled the stopple. Meanwhile, TLC's recording halted while Watkins was hospitalized from complications with her anemia. At the beginning of 2002, Lopes announced that she had signed a solo deal with the infamous Suge Knight's new label Tha Row, for which she would begin recording a followup to the unreleased Supernova under the bring up N.I.N.A. (New Identity Non-Applicable). Sadly, she would never suffer the chance. Vacationing in her favourite pickup patch, Honduras, Lopes was driving a rented SUV with at least seven (maybe eighter from Decatur) passengers. Reportedly hurrying, she baffled control of the vehicle, which flipped all over; she was the but member of the company to be in solemn injured, and died from severe tip dog harm on April 25, 2002. The surviving members of TLC announced their design to fill out the album they'd begun, though without their almost vibrant character the group's long-term future remained in uncertainty. |
Tuesday 19 August 2008
Dendreon Initiates Second Of Two New Phase 2 Trials Of PROVENGE For Prostate Cancer
�Dendreon Corporation
(Nasdaq: DNDN) announced that the Company has initiated its second of
deuce new Phase 2 trials of PROVENGE(R) (sipuleucel-T), Dendreon's
investigational active cellular immunotherapy for the treatment of advanced
prostate cancer. The multicenter tryout, called ProACT (PROstate Active
Cellular Therapy), has begun enrolling great hundred patients with metastatic,
androgenic hormone independent prostate gland cancer.
All patients will receive active treatment merely will be randomized into
one of three cohorts which volition receive PROVENGE manufactured with
different concentrations of the immunizing antigen. Patients will receive
ternary infusions of PROVENGE, each two weeks apart. The trial is being
conducted by Dendreon to explore the effect of antigen concentration on
CD54 upregulation, a measure of mathematical product potency, as well as the immune
response. Overall survival data will as well be collected. The enrolment
criteria ar essentially the same as the criteria for the Phase 3 IMPACT
(IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B)
study, which completed enrollment in October 2007 and, upon receipt of
positive data, will serve as the primary study for amending Dendreon's
Biologics License Application (BLA) for PROVENGE.
"We are grateful for the continued support from patients, physicians
and patient advocates and are pleased to be able to provide them with
access to PROVENGE while we await results from the IMPACT run," stated
Mitchell H. Gold, president and chief executive officer of Dendreon.
ProACT is the second of two studies the Company is initiating. Dendreon
latterly announced it had begun enrolling patients in a 40-subject,
single-center trial called NeoACT (NEOadjuvant Active Cellular
immunoTherapy), or P07-1, which is existence conducted at UCSF Helen Diller
Family Comprehensive Cancer Center.
About Prostate Cancer
Prostate cancer is the well-nigh common non-skin cancer in the United States
and the third most mutual cancer world-wide. More than one one thousand thousand men in
the United States bear prostate crab, with an estimated 186,320 modern cases
expected to be diagnosed in 2008, and approximately 28,660 work force expected to
die this year from the disease. Currently thither are limited treatment
options for men with advanced, metastatic prostate cancer.
About Active Cellular Immunotherapy with PROVENGE
PROVENGE may represent the first intersection in a new class of active
cellular immunotherapies (ACIs) that are unambiguously designed to use lively
human cells to lease the patient's own immune system with the goal of
eliciting a specific long-lasting response against malignant neoplastic disease. Active cellular
immunotherapy holds promise because it crataegus oxycantha provide patients with a
meaningful clinical benefit, such as survival, combined with low toxicity.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to
quarry cancer and transform lives through the discovery, development and
commercialization of novel therapeutics. The Company applies its expertise
in antigen identification, technology and cell processing to produce
active cellular immunotherapy product candidates designed to stimulate an
immune response. Dendreon is also development an orally-available small
speck that targets Trp-p8 that could be applicable to multiple types of
cancer as well as benign prostatic hyperplasia. The Company has its
headquarters in Seattle, Washington and is traded on the Nasdaq Global
Market under the symbol DNDN. For more information about the Company and
its programs, impose http://www.dendreon.com.
Except for historical data contained herein, this news release
contains forward-looking statements that ar subject to risks and
uncertainties surrounding the efficacy of PROVENGE to handle men woe
from prostate cancer, risks and uncertainties surrounding the presentation
of data to the FDA and
(Nasdaq: DNDN) announced that the Company has initiated its second of
deuce new Phase 2 trials of PROVENGE(R) (sipuleucel-T), Dendreon's
investigational active cellular immunotherapy for the treatment of advanced
prostate cancer. The multicenter tryout, called ProACT (PROstate Active
Cellular Therapy), has begun enrolling great hundred patients with metastatic,
androgenic hormone independent prostate gland cancer.
All patients will receive active treatment merely will be randomized into
one of three cohorts which volition receive PROVENGE manufactured with
different concentrations of the immunizing antigen. Patients will receive
ternary infusions of PROVENGE, each two weeks apart. The trial is being
conducted by Dendreon to explore the effect of antigen concentration on
CD54 upregulation, a measure of mathematical product potency, as well as the immune
response. Overall survival data will as well be collected. The enrolment
criteria ar essentially the same as the criteria for the Phase 3 IMPACT
(IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B)
study, which completed enrollment in October 2007 and, upon receipt of
positive data, will serve as the primary study for amending Dendreon's
Biologics License Application (BLA) for PROVENGE.
"We are grateful for the continued support from patients, physicians
and patient advocates and are pleased to be able to provide them with
access to PROVENGE while we await results from the IMPACT run," stated
Mitchell H. Gold, president and chief executive officer of Dendreon.
ProACT is the second of two studies the Company is initiating. Dendreon
latterly announced it had begun enrolling patients in a 40-subject,
single-center trial called NeoACT (NEOadjuvant Active Cellular
immunoTherapy), or P07-1, which is existence conducted at UCSF Helen Diller
Family Comprehensive Cancer Center.
About Prostate Cancer
Prostate cancer is the well-nigh common non-skin cancer in the United States
and the third most mutual cancer world-wide. More than one one thousand thousand men in
the United States bear prostate crab, with an estimated 186,320 modern cases
expected to be diagnosed in 2008, and approximately 28,660 work force expected to
die this year from the disease. Currently thither are limited treatment
options for men with advanced, metastatic prostate cancer.
About Active Cellular Immunotherapy with PROVENGE
PROVENGE may represent the first intersection in a new class of active
cellular immunotherapies (ACIs) that are unambiguously designed to use lively
human cells to lease the patient's own immune system with the goal of
eliciting a specific long-lasting response against malignant neoplastic disease. Active cellular
immunotherapy holds promise because it crataegus oxycantha provide patients with a
meaningful clinical benefit, such as survival, combined with low toxicity.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to
quarry cancer and transform lives through the discovery, development and
commercialization of novel therapeutics. The Company applies its expertise
in antigen identification, technology and cell processing to produce
active cellular immunotherapy product candidates designed to stimulate an
immune response. Dendreon is also development an orally-available small
speck that targets Trp-p8 that could be applicable to multiple types of
cancer as well as benign prostatic hyperplasia. The Company has its
headquarters in Seattle, Washington and is traded on the Nasdaq Global
Market under the symbol DNDN. For more information about the Company and
its programs, impose http://www.dendreon.com.
Except for historical data contained herein, this news release
contains forward-looking statements that ar subject to risks and
uncertainties surrounding the efficacy of PROVENGE to handle men woe
from prostate cancer, risks and uncertainties surrounding the presentation
of data to the FDA and
Saturday 9 August 2008
Lutan Fayah
Artist: Lutan Fayah
Genre(s):
Reggae
Discography:
Armegeddon war
Year:
Tracks: 13
A rootsy reggae singer with messages of single, love, and justice deep embedded in his music, Lutan Fyah was natural in the parish of St. Catherine, Jamaica, with music in his blood. With his grandfather running a sound system, artists such as Lieutenant Stitchie, Papa San, Lady G., and the fabled Dennis Brown would often date the gang home. Fyah aspired to become a renowned isaac M. Singer himself, just now he also took his soccer playing severely and coupled a professional squad after finish high school. He gave up sports in 1999 and began an internship at Buju Banton's Gargamel label. He went on to record some tracks for Banton's label along with some free-lance work for other producers, ahead isaac M. Singer Jah Mason came along in 2001 and offered Fyah the support slot on his world hitch. Three old old age later he made his full-length debut with Dem No Know Demself on the Minor7Flat5 label. Time and Place on the Lustre Kings label followed in 2005. A twelvemonth later he released dickens albums, Phantasm War on Greensleeves and Salubrious Lifestyle on VP.
Recreation And Park Agencies Play A Key Role In Promoting Healthy Lifestyles
Tuesday 1 July 2008
Jennifer Hudson's 'Spotlight'
’Spotlight’ (Arista): B+
On the bounceworthy lead single off her forthcoming debut album, “American Idol” loser/Oscar winner Hudson questions whether she’s captivated by her overprotective lover or simply held captive. The beat sounds like a cross between Alicia Keys’ “No One” and about 10 other songs co-writer Ne-Yo and production team Stargate have created in tandem, upping the radio-ready factor but lending “Spotlight” a been-there-done-that feeling. Still, Hudson makes the track her own by delivering it with believable angst and the kind of powerhouse singing that catapulted her from cruise ship performer to “Idol” finalist and bona fide “Dreamgirl.”
On the bounceworthy lead single off her forthcoming debut album, “American Idol” loser/Oscar winner Hudson questions whether she’s captivated by her overprotective lover or simply held captive. The beat sounds like a cross between Alicia Keys’ “No One” and about 10 other songs co-writer Ne-Yo and production team Stargate have created in tandem, upping the radio-ready factor but lending “Spotlight” a been-there-done-that feeling. Still, Hudson makes the track her own by delivering it with believable angst and the kind of powerhouse singing that catapulted her from cruise ship performer to “Idol” finalist and bona fide “Dreamgirl.”
Subscribe to:
Posts (Atom)